|Day Low/High||27.10 / 27.80|
|52 Wk Low/High||9.55 / 31.70|
Investors in AxoGen Inc saw new options begin trading this week, for the February 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AXGN options chain for the new February 16th contracts and identified one put and one call contract of particular interest.
In recent trading, shares of AxoGen Inc have crossed above the average analyst 12-month target price of $31.00, changing hands for $31.05/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Several presentations will highlight the growing body of clinical evidence supporting the company's platform for nerve repair
Parade float will highlight the life-changing power of tissue and organ donation
Investors in AxoGen Inc saw new options begin trading this week, for the July 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 231 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Record Q3 Revenue of $16.0 million, representing 43% growth over prior year
Award recognizes company's contribution to Florida's life sciences industry
AxoGen offers Oral and Maxillofacial surgeons solutions for the repair of peripheral nerve damage
In recent trading, shares of AxoGen Inc have crossed above the average analyst 12-month target price of $16.15, changing hands for $16.35/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
Growing body of data related to repair of mixed, motor, and long-gap nerve injuries will be reviewed at hosted symposium
Record Q2 Revenue of $15.2 million, representing 46% growth over prior year
Record Q1 Revenue of $12.2 million, representing 51% growth over prior year
Investors considering a purchase of AxoGen Inc shares, but cautious about paying the going market price of $11.45/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the October put at the $10 strike, which has a bid at the time of this writing of 65 cents.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.